Clinical Trial Results: Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists [Phase 2]

View source ↗

Summary

Phase 2 trial assessing RDX-002 effects on postprandial triglycerides in patients stopping GLP-1 agonists; results completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triglyceride Metabolic Disorder
• Weight Gain After Glp-1 Therapy

Drugs mentioned

• RDX-002

Snippet

Sponsor: Response Pharmaceuticals | Conditions: Triglycerides, Weight Gain Trajectory | Phase 2 | Status: COMPLETED | Results posted: 2026-07-02